Kolexia
Rodrigues Manuel Oncologie médicale
Rodrigues Manuel
Oncologie médicale
Clcc Institut Curie
Paris, France
209 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Mélanome Tumeurs du sein Tumeurs de l'uvée Tumeurs de l'ovaire Métastase tumorale Récidive tumorale locale Carcinomes Tumeurs de l'endomètre Tumeurs du col de l'utérus

Collaborateurs

Voir plus
Gregoire-Cassoux Nathalie
Gregoire-Cassoux Nathalie
Clcc Institut Curie, Paris, France
Stern Marc-Henri
Stern Marc-Henri
Clcc Institut Curie, Paris, France
Piperno-Neumann Sophie
Piperno-Neumann Sophie
Clcc Institut Curie, Paris, France
Mariani Pascale
Mariani Pascale
Clcc Institut Curie, Paris, France

Industries

Voir plus
GSK
24 collaboration(s)
Dernière en 2023
AstraZeneca
14 collaboration(s)
Dernière en 2023
MSD
12 collaboration(s)
Dernière en 2023
PUBLICLIN
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
PLUME: A Phase II, Monocentric, Single Arm Trial Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients
Essai Clinique (Merck & Co.)   19 mars 2024
ALCINA: Analysis of Circulating Tumor Markers in the Blood
Essai Clinique (Institut Curie)   01 février 2024
RadioPARP: A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Essai Clinique (AstraZeneca)   29 janvier 2024
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0): Study to Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (R0)
Essai Clinique (Institut Curie)   29 janvier 2024
SFC in 2024.
Bulletin du cancer   22 janvier 2024
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Essai Clinique (AstraZeneca)   15 janvier 2024
A 2023 inventory in oncology news.
Bulletin du cancer   05 janvier 2024
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
Essai Clinique (Roche)   02 janvier 2024
Familial uveal melanoma and other tumours in 25 families with monoallelic germline MBD4 variants.
Journal of the National Cancer Institute   07 décembre 2023
187P Local and systemic anti-tumor response during tumor development in an immune privileged site: The case of uveal melanoma
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023